Tfh: T follicular helper; Tfc: T follicular cytotoxic; Treg: regulatory T; TGF: transforming growth factor
Declarations
Author contributions
Masutaka F wrote and Mihoko F revised the first draft. After English editing was performed, Masutaka F and Mihoko F agreed the final version and submitted the article.
Perusina Lanfranca M, Lin Y, Fang J, Zou W, Frankel T.Biological and pathological activities of interleukin-22. J Mol Med (Berl).2016;94:523–34. [DOI] [PubMed] [PMC]
Ito T, Hirose K, Nakajima H.Bidirectional roles of IL-22 in the pathogenesis of allergic airway inflammation. Allergol Int.2019;68:4–8. [DOI] [PubMed]
Wei HX, Wang B, Li B.IL-10 and IL-22 in mucosal immunity: driving protection and pathology. Front Immunol.2020;11:1315. [DOI] [PubMed] [PMC]
Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int.2017;66:398–403. [DOI] [PubMed]
Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T.Pathogenesis of atopic dermatitis: current paradigm. Iran J Immunol.2019;16:97–107. [DOI] [PubMed]
Furue K, Ito T, Furue M.Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine.2018;111:182–8. [DOI] [PubMed]
Furue K, Ito T, Tsuji G, Kadono T, Furue M.Psoriasis and the TNF/IL23/IL17 axis. G Ital Dermatol Venereol.2019;154:418–24. [DOI] [PubMed]
Furue M, Furue K, Tsuji G, Nakahara T.Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci.2020;21:1275. [DOI]
Hayashida S, Uchi H, Takeuchi S, Esaki H, Moroi Y, Furue M.Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis. J Dermatol Sci.2011;61:78–9. [DOI] [PubMed]
Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol.2012;130:1344–54. [DOI] [PubMed] [PMC]
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol.2018;78:872–81. [DOI] [PubMed]
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol.2019;143:155–72. [DOI] [PubMed]
Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis Is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol.2019;139:1480–9. [DOI] [PubMed] [PMC]
Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol.2019;144:750–63. [DOI] [PubMed]
Fujita H.The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci.2013;72:3–8. [DOI] [PubMed]
Sonnenberg GF, Fouser LA, Artis D.Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol.2011;12:383–90. [DOI] [PubMed]
Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol.2015;135:153–63. [DOI] [PubMed] [PMC]
Ramirez JM, Brembilla NC, Sorg O, Chicheportiche R, Matthes T, Dayer JM, et al. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol.2010;40:2450–9. [DOI] [PubMed]
Chen Y, Tian Z, Peng H.Immunological memory: ILC1s come into view. Cell Mol Immunol.2019;16:895–6. [DOI] [PubMed] [PMC]
Wang S, Xia P, Chen Y, Qu Y, Xiong Z, Ye B, et al. Regulatory innate lymphoid cells control innate intestinal inflammation. Cell.2017;171:201–16. [DOI] [PubMed]
Chun E, Lavoie S, Fonseca-Pereira D, Bae S, Michaud M, Hoveyda HR, et al. Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity. Immunity.2019;51:871–84. [DOI] [PubMed] [PMC]
Furue K, Ito T, Tsuji G, Nakahara T, Furue M.The CCL20 and CCR6 axis in psoriasis. Scand J Immunol.2020;91:e12846. [DOI] [PubMed]
Furue K, Ito T, Tanaka Y, Yumine A, Hashimoto-Hachiya A, Takemura M, et al. Cyto/chemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon. J Dermatol Sci.2019;94:244–51. [DOI] [PubMed]
Furue K, Ito T, Tanaka Y, Hashimoto-Hachiya A, Takemura M, Murata M, et al. The EGFR-ERK/JNK-CCL20 pathway in scratched keratinocytes may underpin Koebnerization in psoriasis patients. Int J Mol Sci.2020;21:434. [DOI]
Bouma G, Zamuner S, Hicks K, Want A, Oliveira J, Choudhury A, et al. CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6+ cells in an experimental suction blister. Br J Clin Pharmacol.2017;83:1976–90. [DOI] [PubMed] [PMC]
Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature.2007;445:648–51. [DOI] [PubMed]
Xu M, Morishima N, Mizoguchi I, Chiba Y, Fujita K, Kuroda M, et al. Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production. Eur J Immunol.2011;41:2828–39. [DOI] [PubMed]
Brembilla NC, Ramirez JM, Chicheportiche R, Sorg O, Saurat JH, Chizzolini C.In vivo dioxin favors interleukin-22 production by human CD4+ T cells in an aryl hydrocarbon receptor (AhR)-dependent manner. PLoS One.2011;6:e18741. [DOI] [PubMed] [PMC]
Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol.2011;13:144–51. [DOI] [PubMed] [PMC]
Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature.2008;453:106–9. [DOI] [PubMed]
Nguyen CT, Bloch Y, Składanowska K, Savvides SN, Adamopoulos IE.Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: a molecular insight. Clin Immunol.2019;206:15–22. [DOI] [PubMed] [PMC]
Furue M, Tsuji G, Mitoma C, Nakahara T, Chiba T, Morino-Koga S, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci.2015;80:83–8. [DOI] [PubMed]
Furue M.Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4– JAK–STAT6/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J Clin Med.2020;9:3741. [DOI]
Furue M.Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Iimplications in atopic dermatitis. Int J Mol Sci.2020;21:5382. [DOI]
Kiss EA, Vonarbourg C, Kopfmann S, Hobeika E, Finke D, Esser C, et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science.2011;334:1561–5. [DOI] [PubMed]
Schiering C, Wincent E, Metidji A, Iseppon A, Li Y, Potocnik AJ, et al. Feedback control of AHR signalling regulates intestinal immunity. Nature.2017;542:242–5. [DOI] [PubMed] [PMC]
Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, Galanou M, et al. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol.2013;133:2023–30. [DOI] [PubMed] [PMC]
Yu J, Luo Y, Zhu Z, Zhou Y, Sun L, Gao J, et al. A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor. J Allergy Clin Immunol.2019;143:2108–19. [DOI] [PubMed]
Fritsche E, Schäfer C, Calles C, Bernsmann T, Bernshausen T, Wurm M, et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A.2007;104:8851–6. [DOI] [PubMed] [PMC]
Stockinger B, Di Meglio P, Gialitakis M, Duarte JH.The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol.2014;32:403–32. [DOI] [PubMed]
Liu G, Asanoma K, Takao T, Tsukimori K, Uchi H, Furue M, et al. Arylhydrocarbon receptor SNP-130 C/T associates with dioxins susceptibility through regulating its receptor activity and downstream effectors including interleukin 24. Toxicol Lett.2015;232:384–92. [DOI] [PubMed]
Vu YH, Hashimoto-Hachiya A, Takemura M, Yumine A, Mitamura Y, Nakahara T, et al. IL-24 negatively regulates keratinocyte differentiation induced by Tapinarof, an aryl hydrocarbon receptor modulator: implication in the treatment of atopic dermatitis. Int J Mol Sci.2020;21:9412. [DOI]
Yu YH, Furue M, Tsuji G.The role of IL-24 in atopic dermatitis. Explor Immunol. 2021;1:4–15. [DOI]
Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol.2002;3:673–80 [DOI] [PubMed]
Hammad H, Lambrecht BN.Barrier epithelial cells and the control of Type 2 immunity. Immunity.2015;43:29–40. [DOI] [PubMed]
Dainichi T, Kitoh A, Otsuka A, Nakajima S, Nomura T, Kaplan DH, et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat Immunol.2018;19:1286–98. [DOI] [PubMed]
Zheng R, Chen FH, Gao WX, Wang D, Yang QT, Wang K, et al. The TH2-polarizing function of atopic interleukin 17 receptor B-positive dendritic cells up-regulated by lipopolysaccharide. Ann Allergy Asthma Immunol.2017;118:474–82. [DOI] [PubMed]
Nechama M, Kwon J, Wei S, Kyi AT, Welner RS, Ben-Dov IZ, et al. The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. Nat Commun.2018;9:1603. [DOI] [PubMed] [PMC]
Czarnowicki T, He H, Krueger JG, Guttman-Yassky E.Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol.2019;143:1–11. [DOI] [PubMed]
Xie L, Moroi Y, Takahara M, Tsuji G, Oba J, Hayashida S, et al. CD10 expressed by fibroblasts and melanoma cells degrades endothelin-1 secreted by human keratinocytes. Eur J Dermatol.2011;21:505–9. [DOI] [PubMed]
Aktar MK, Kido-Nakahara M, Furue M, Nakahara T.Mutual upregulation of endothelin-1 and IL-25 in atopic dermatitis. Allergy.2015;70:846–54. [DOI] [PubMed]
Eto A, Nakahara T, Kido-Nakahara M, Tsuji G, Furue M.Acrosyringeal endothelin-1 expression: potential for fostering melanocytes in volar sites. J Dermatol.2020;47:924–5. [DOI] [PubMed]
Nakahara T, Kido-Nakahara M, Ohno F, Ulzii D, Chiba T, Tsuji G, et al. The pruritogenic mediator endothelin-1 shifts the dendritic cell-T-cell response toward Th17/Th1 polarization. Allergy.2018;73:511–5. [DOI] [PubMed]
Kido-Nakahara M, Buddenkotte J, Kempkes C, Ikoma A, Cevikbas F, Akiyama T, et al. Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus. J Clin Invest.2014;124: 2683–95. [DOI] [PubMed] [PMC]
Nakahara T, Kido-Nakahara M, Furue M.Potential role of endothelin-1 in atopic dermatitis. Curr Treat Options Allergy.2019;6:156–63. [DOI]
Kido-Nakahara M, Wang B, Ohno F, Tsuji G, Ulzii D, Takemura M, et al. Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan. Allergy.2021;76:291–301. [DOI] [PubMed]
Nakahara T, Kido-Nakahara M, Ulzii D, Miake S, Fujishima K, Sakai S, et al. Topical application of endothelin receptor a antagonist attenuates imiquimod-induced psoriasiform skin inflammation. Sci Rep.2020;10:9510. [DOI] [PubMed] [PMC]
Fukaya T, Fukui T, Uto T, Takagi H, Nasu J, Miyanaga N, et al. Pivotal role of IL-22 binding protein in the epithelial autoregulation of interleukin-22 signaling in the control of skin inflammation. Front Immunol.2018;9:1418. [DOI] [PubMed] [PMC]
Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol.2001;166:7096–103. [DOI] [PubMed]
Xu W, Presnell SR, Parrish-Novak J, Kindsvogel W, Jaspers S, Chen Z, et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A.2001;98:9511–6. [DOI] [PubMed] [PMC]
Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. J Immunol.2007;178:5973–81. [DOI] [PubMed]
Jones BC, Logsdon NJ, Walter MR.Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure.2008;16:1333–44. [DOI] [PubMed] [PMC]
Martin JCJ, Bériou G, Heslan M, Chauvin C, Utriainen L, Aumeunier A, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol.2014;7:101–13. [DOI] [PubMed] [PMC]
Pelczar P, Witkowski M, Perez LG, Kempski J, Hammel AG, Brockmann L, et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science.2016;354:358–62. [DOI] [PubMed]
Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol.2007;178:2229–40. [DOI] [PubMed]
Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, Hirakawa S, et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol.2009;39:2779–88. [DOI] [PubMed]
Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, et al. A novel role for IL-22R1 as a driver of inflammation. Blood.2011;117:575–84. [DOI] [PubMed] [PMC]
Lindroos J, Svensson L, Norsgaard H, Lovato P, Moller K, Hagedorn PH, et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J Invest Dermatol.2011;131:1110–8. [DOI] [PubMed]
Lifshiz Zimon R, Lerman G, Elharrar E, Meningher T, Barzilai A, Masalha M, et al. Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis. J Control Release.2018;284:103–11. [DOI] [PubMed]
Masalha M, Gur-Wahnon D, Meningher T, Ben-Dov IZ, Kassem R, Sidi Y, et al. IL6R is a target of miR-197 in human keratinocytes. Exp Dermatol. Forthcoming 2020.
Yamamoto H, Kemper C.Complement and IL-22: partnering up for border patrol. Immunity.2014; 41:511–3. [DOI] [PubMed]
Hasegawa M, Yada S, Liu MZ, Kamada N, Muñoz-Planillo R, Do N, et al. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity.2014;41:620–32. [DOI] [PubMed] [PMC]
Rothhammer V, Quintana FJ.The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol.2019;19:184–97. [DOI] [PubMed]
Furue M, Uchi H, Mitoma C, Hashimoto-Hachiya A, Tanaka Y, Ito T, et al. Implications of tryptophan photoproduct FICZ in oxidative stress and terminal differentiation of keratinocytes. G Ital Dermatol Venereol.2019;154:37–41. [DOI] [PubMed]
Peng F, Tsuji G, Zhang JZ, Chen Z, Furue M.Potential role of PM2.5 in melanogenesis. Environ Int.2019;132:105063. [DOI] [PubMed]
Furue M, Hashimoto-Hachiya A, Tsuji G.Antioxidative phytochemicals accelerate epidermal terminal differentiation via the AHR-OVOL1 pathway: implications for atopic dermatitis. Acta Derm Venereol.2018;98:918–23. [DOI] [PubMed]
Jin SH, Choi D, Chun YJ, Noh M.Keratinocyte-derived IL-24 plays a role in the positive feedback regulation of epidermal inflammation in response to environmental and endogenous toxic stressors. Toxicol Appl Pharmacol.2014;280:199–206. [DOI] [PubMed]
Gläser R, Meyer-Hoffert U, Harder J, Cordes J, Wittersheim M, Kobliakova J, et al. The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol.2009;129:641–9. [DOI] [PubMed]
Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol.2010;184:5263–70. [DOI] [PubMed]
Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F.IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol.2005;174:3695–702. [DOI] [PubMed]
Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol.2011;41:1894–901. [DOI] [PubMed]
Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol.2008;159:1092–102. [DOI] [PubMed] [PMC]
Avitabile S, Odorisio T, Madonna S, Eyerich S, Guerra L, Eyerich K, et al. Interleukin-22 promotes wound repair in diabetes by improving keratinocyte pro-healing functions. J Invest Dermatol.2015;135: 2862–70. [DOI] [PubMed]
Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS.Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol.2011;165:492–8. [DOI] [PubMed]
Noh M, Yeo H, Ko J, Kim HK, Lee CH.MAP17 is associated with the T-helper cell cytokine-induced down-regulation of filaggrin transcription in human keratinocytes. Exp Dermatol.2010;19:355–62. [DOI] [PubMed]
Zhuang L, Ma W, Yan J, Zhong H.Evaluation of the effects of IL 22 on the proliferation and differentiation of keratinocytes in vitro. Mol Med Rep.2020;22:2715–22. [DOI] [PubMed] [PMC]
Ekman AK, Bivik Eding C, Rundquist I, Enerbäck C.IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis. J Invest Dermatol.2019;139:1564–73. [DOI] [PubMed]
Jang M, Kim H, Kim Y, Choi J, Jeon J, Hwang Y, et al. The crucial role of IL-22 and its receptor in thymus and activation regulated chemokine production and T-cell migration by house dust mite extract. Exp Dermatol.2016;25:598–603. [DOI] [PubMed]
Kim Y, Lee J, Kim J, Choi CW, Hwang YI, Kang JS, et al. The pathogenic role of interleukin-22 and its receptor during UVB-induced skin inflammation. PLoS One.2017;12:e0178567. [DOI] [PubMed] [PMC]
Mitamura Y, Nunomura S, Nanri Y, Ogawa M, Yoshihara T, Masuoka M, et al. The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation. Allergy.2018;73:1881–91. [DOI] [PubMed]
Mitamura Y, Nunomura S, Furue M, Izuhara K.IL-24: a new player in the pathogenesis of pro-inflammatory and allergic skin diseases. Allergol Int.2020;6:405–411. [DOI]
Bansal G, Das D, Hsieh CY, Wang YH, Gilmore BA, Wong CM, et al. IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells. Cell Signal.2013;25:2727–33. [DOI] [PubMed] [PMC]
Cho KA, Suh JW, Lee KH, Kang JL, Woo SY.IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol.2012;24:147–58. [DOI] [PubMed]
Zhang J, Sun L, Li W, Wang Y, Li X, Liu Y.Overexpression of macrophage stimulating 1 enhances the anti-tumor effects of IL-24 in esophageal cancer via inhibiting ERK-Mfn2 signaling-dependent mitophagy. Biomed Pharmacother.2019;114:108844. [DOI] [PubMed]
Palombo R, Savini I, Avigliano L, Madonna S, Cavani A, Albanesi C, et al. Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model. Cell Death Dis.2016;7:e2344. [DOI] [PubMed] [PMC]
Hebert KD, Mclaughlin N, Galeas-Pena M, Zhang Z, Eddens T, Govero A, et al. Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection. Mucosal Immunol.2020;13:64–74. [DOI] [PubMed] [PMC]
Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y.Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One.2016;11:e0161759. [DOI] [PubMed] [PMC]
Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol.2019;143: 142–54. [DOI] [PubMed]
